Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

PRECISION-T2D-studien: Presisjonsernæringsstudie for type 2-diabetes

24. september 2026 oppdatert av: Westlake University

Food plays a crucial role in determining blood glucose levels, especially in people with type 2 diabetes. Precision nutrition, which involves individually tailored dietary interventions, can be a powerful tool in managing blood glucose levels in people with type 2 diabetes. Previous studies found that changes in gut microbiota resulted from the dietary intervention, such as plant-based diet, might subsequently lead to different glycemic responses, and then different health outcomes.

In this study, the investigators will characterize the blood glucose dynamics and gut microbiota of individuals with type 2 diabetes. They aim to assess the influence of plant-based diet on gut microbiota; they will also investigate the influence of gut microbiota on glycemic responses. Additionally, a series of individual N-of-1 trails will be integrated to compare the effects of a white bread breakfast and a whole wheat bread breakfast on glucose metabolism at the individual level.

Studieoversikt

Detaljert beskrivelse

Choice of design: The study is a two-arm intervention study integrated with N-of-1 design.

Study population: Patients with type 2 diabetes.

Screening Assessment: Prospective participants will be selected based on the pre-defined inclusion and exclusion criteria. Recruitment will be done over the phone and via the social media.

Study duration: Each participant will take part in the study for a period of up to 1 month at baseline and have follow-up visits every 1-2 years.

Dietary intervention:

The PRECISION-T2D is a dietary intervention study. Upon admission, patients will be randomly assigned to two groups: plant-based diet and conventional diabetic diet. Throughout the hospitalization, all participants (n=200) will be given standardized meals. A dietitian will design the diet for both plant-based and conventional diabetic diet groups following 2023 Chinese Diabetes Society guidelines. Both diets comprised approximately 50-65% of energy from carbohydrates, 20-30% of energy from fat, 15-20% from protein. The plant-based diet had higher fiber content (25-30g) compared to the conventional diabetic diet (15-20g). Participants will be asked to consume the entire amount of food indicated for the standardized meals and to record any leftover food. All participants will be asked to track their meals, snacks and drinks with instructions on how to record their daily dietary information. Participants will also be advised not to modify their exercise habits during the course of the study. Upon discharge, Participants in the plant-based diet arm will be recommended to consume more fiber-rich foods, including whole grains, fruits, legumes and vegetables; to moderate their intake of fish, eggs and dairy products; and to avoid other animal products. Participants in the conventional diabetic diet arm will be recommended to have a diet following 2023 Chinese Diabetes Society guidelines. Individual N-of-1 trial design will be employed to all participants during day one to day twelve to compare the difference of postprandial glucose response to white bread or whole wheat bread. These two standard breakfasts will appear in pseudo-random order. During the participants' first baseline visit day, they will be asked to complete a baseline questionnaire to collect information on their lifestyle, dietary habits, history of medications, sleep quality and appetite. Anthropometric measurements, ultrasonography evaluation, and laboratory tests will be taken using standard protocols. Participants will then be asked to wear a continuous glucose monitor (CGM) for 14-day blood glucose monitoring, which will be done by a nurse. On day 14, participants will be asked to come in for a clinical visit where they will receive their CGM report and provide blood, saliva, urine and stool samples. On day 30, participants will be asked to come in for another clinical visit where they will provide blood, saliva, urine and stool samples.

Studietype

Intervensjonell

Registrering (Faktiske)

144

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Zhejiang
      • Hangzhou, Zhejiang, Kina, 310058
        • Hangzhou Third People's Hospital
      • Hangzhou, Zhejiang, Kina, 310030
        • Westlake University

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

35 år til 75 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Diagnosed with type 2 diabetes;
  • Living in Hangzhou for at least five years;
  • Have the willingness or ability to complete the intervention and sample collection

Exclusion Criteria:

  • Mental and physical disability;
  • Already is a vegetarian;
  • Cancer and serious complications from type 2 diabetes, such as renal failure;
  • Using insulin for more than 5 years;
  • Unstable medical/medication status;
  • Current alcohol or drug abuse;
  • Taking antibiotics in the last three months

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Annen
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Dobbelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Plant-based diet

Participants in this arm will be recommended to consume more fiber-rich foods, including whole grains, fruits, legumes and vegetables; to moderate their intake of fish, eggs and dairy products; and to avoid other animal products. All participants are instructed not to modify their exercise habits during the intervention period.

After wearing CGM on Day 1, participants will be provided with white bread (76-77g) and milk (250mL) for breakfast on Day 3, Day 4, Day 7, Day 8, Day 10, Day 12.

Andre navn:
  • Frokost A

After wearing CGM on Day 1, participants will be provided with wheat bread (85-86g) and milk (250mL) for breakfast on Day 2, Day 5, Day 6, Day 9, Day 11, Day 13.

Andre navn:
  • Frokost B

After wearing CGM on Day 1, participants will be asked to follow the plant-based diet in next 30 days.

Participants will be visited every 1-2 years. At each visit, face-to-face interviews, specimen collection, anthropometric measurements, ultrasonography evaluation, laboratory tests, and multi-omics data will be conducted.

Eksperimentell: Conventional diabetic diet

Participants in this arm will be recommended to have a diet following 2023 Chinese Diabetes Society guidelines. All participants are instructed not to modify their exercise habits during the intervention period.

After wearing CGM on Day 1, participants will be provided with white bread (76-77g) and milk (250mL) for breakfast on Day 3, Day 4, Day 7, Day 8, Day 10, Day 12.

Andre navn:
  • Frokost A

After wearing CGM on Day 1, participants will be provided with wheat bread (85-86g) and milk (250mL) for breakfast on Day 2, Day 5, Day 6, Day 9, Day 11, Day 13.

Andre navn:
  • Frokost B

Participants will be visited every 1-2 years. At each visit, face-to-face interviews, specimen collection, anthropometric measurements, ultrasonography evaluation, laboratory tests, and multi-omics data will be conducted.

Volunteers will be asked to have a diet following 2023 Chinese Diabetes Society guidelines in next 30 days.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Continuous glucose monitoring-derived mean blood glucose
Tidsramme: 2 weeks

Real-time glucose profiles will be recorded using continuous glucose monitoring. Average of all glucose measurements during the up to 14 days CGM wear will be calculated in mmol/L.

2 weeks
Continuous glucose monitoring-derived time-in-range
Tidsramme: 2 weeks

Real-time glucose profiles will be recorded using continuous glucose monitoring. Percentage of glucose measurements that wear in the range of 3.9-10.0 mmol/L during the up to 14 days CGM will be calculated.

2 weeks
Continuous glucose monitoring-derived coefficient of variation
Tidsramme: two weeks

Continuous glucose monitoring-derived time-in-range Real-time glucose profiles will be recorded using continuous glucose monitoring. Coefficient of variation was defined as standard deviation divided by mean glucose and multiplied by 100, during the up to 14 days wear.

two weeks
Changes in gut microbiome profile
Tidsramme: Day 1, 15 and 31

Shotgun metagenomic sequencing will be performed in stool samples.

Day 1, 15 and 31

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Changes in fasting blood glucose
Tidsramme: Day 1, 15 and 31

Fasting glucose will be examined in mmol/L.

Day 1, 15 and 31
Changes in fasting blood C-peptide
Tidsramme: Day 1, 15 and 31

Fasting blood C-peptide will be examined in μg/L.

Day 1, 15 and 31
Changes in fasting blood HbA1c
Tidsramme: Day 1, 15 and 31

Fasting blood HbA1c will be examined in %.

Day 1, 15 and 31
Changes in lipid metabolism
Tidsramme: Day 1, 15 and 31

Triglyceride, cholesterol, high density lipoprotein cholesterol and low density lipoprotein cholesterol will be examined in mmol/L.

Day 1, 15 and 31

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Ju-Sheng Zheng, PhD, Westlake University

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

17. juli 2023

Primær fullføring (Faktiske)

4. januar 2026

Studiet fullført (Faktiske)

4. januar 2026

Datoer for studieregistrering

Først innsendt

23. mars 2023

Først innsendt som oppfylte QC-kriteriene

30. mai 2023

Først lagt ut (Faktiske)

2. juni 2023

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

29. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

24. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere